TYP
vs
S
S&P/ASX 300
TYP
Over the past 12 months, TYP has outperformed S&P/ASX 300, delivering a return of +3% compared to S&P/ASX 300's +1% growth.
Stocks Performance
TYP vs S&P/ASX 300
Performance Gap
TYP vs S&P/ASX 300
Performance By Year
TYP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Exopharm Ltd
Glance View
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.
